Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Elektrofi Inc. currently manages a patent portfolio with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is being reviewed by 1 distinct examiner, GREENE, IVAN A, who is also the busiest examiner with 1 busiest examiner pending action. The prosecution is concentrated within 1 distinct art unit, reflecting a narrow technical focus for the company's current USPTO filings.
For a patent practitioner, this data indicates that the entirety of the company's immediate prosecution success relies on the outcome of this 1 pending office action. Since there is only 1 distinct examiner involved, there are no competing examiner perspectives to navigate within the Biotechnology & Pharmaceuticals sector. The matching count of 1 pending office action and 1 busiest examiner pending action under GREENE, IVAN A means that all prosecution resources are directed toward a single point of contact. This concentration in 1 distinct art unit and under 1 distinct examiner allows for a highly specialized and streamlined communication strategy, though it also means the portfolio lacks the diversification that comes with multiple pending matters across different examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759592 | Droplet Formation and Particle Morphology | GREENE, IVAN A | 7d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17759592 | Droplet Formation and Particle Morphology | GREENE, IVAN A | 1619 | §103Other | Non-Final OA | 7d | Pending | Jul 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElektrofi Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ivan A Greene has the most, with 1 of Elektrofi Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.